L2L Microarray Analysis Tool
Results for R06AD.profile.u50
| Results summary | View all lists in L2L MDB | View all genes in R06AD.profile.u50 |
| List Name | Description | Total probes |
Expected matches |
Actual matches |
Fold Enrichment |
Binomial p-value |
|---|---|---|---|---|---|---|
| bay_pbmc_2hr_up | Up-regulated at 2 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 606 | 1.50 | 10 | 6.68 | 3.84e-06 |
| hypoxia_fibro_young_up | Upregulated by hypoxia in normal fibroblasts from young, but not old, donors (Table 1) | 15 | 0.04 | 3 | 80.91 | 6.72e-06 |
| bay_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 544 | 1.34 | 9 | 6.69 | 1.13e-05 |
| bay_pbmc_24hr_up | Up-regulated at 24 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 202 | 0.50 | 5 | 10.01 | 1.64e-04 |
| idx_tsa_dn_cluster4 | Strongly down-regulated at 8-48 hours during differentiation of 3T3-L1 fibroblasts into adipocytes with IDX (insulin, dexamethasone and isobutylxanthine), vs. fibroblasts treated with IDX + TSA to prevent differentiation (cluster 4) | 46 | 0.11 | 3 | 26.38 | 2.12e-04 |
| alk5_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 6 | 6.99 | 2.58e-04 |
| alk5_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK5,, which activates the Smad2/3 pathway, in human microvessel endothelial cells (HMVEC). | 347 | 0.86 | 6 | 6.99 | 2.58e-04 |
| as3_hek293_dn | Downregulated in HEK293 cells by treatment with arsenite | 12 | 0.03 | 2 | 67.42 | 3.97e-04 |
| il2_pbmc_6hr_up | Up-regulated at 6hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 530 | 1.31 | 7 | 5.34 | 4.12e-04 |
| cpr_null_liver_up | Up-regulated in mouse liver tissue from mice in which NADPH-cytochrome P450 reductase (CPR) was specifically deleted in the liver by cre-lox recombination, versus lox-only controls | 64 | 0.16 | 3 | 18.96 | 5.62e-04 |
| icf_dn | Downregulated in B-cells from ICF syndrome (DNMT3B) compared to normals | 23 | 0.06 | 2 | 35.18 | 1.49e-03 |
| il2_pbmc_4hr_up | Up-regulated at 4 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 510 | 1.26 | 6 | 4.76 | 1.88e-03 |
| il2_pbmc_48hr_up | Up-regulated at 48 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 511 | 1.26 | 6 | 4.75 | 1.90e-03 |
| adipogenesis_hmsc_class3_up | Up-regulated 3-14 days following the differentiation of human bone marrow mesenchymal stem cells (hMSC) into adipocytes, versus untreated hMSC cells (Class III) | 109 | 0.27 | 3 | 11.13 | 2.61e-03 |
| hypoxia_normal_up | Upregulated by hypoxia in normal, RPTEC renal cells (Fig. 3) | 376 | 0.93 | 5 | 5.38 | 2.64e-03 |
| bleo_human_lymph_high_4hrs_up | Up-regulated at 4 hours following treatment of human lymphocytes (TK6) with a high dose of bleomycin | 32 | 0.08 | 2 | 25.28 | 2.88e-03 |
| cpr_low_liver_up | Up-regulated in mouse liver tissue from mice with reduced liver expression of NADPH-cytochrome P450 reductase (CPR), versus normal controls | 32 | 0.08 | 2 | 25.28 | 2.88e-03 |
| 5azac_hepg2_up | Up-regulated in human hepatoma cells (HepG2) following 48 hrs treatment with 2.5 microM 5-aza-2-deoxycytidine (5azaC). | 1630 | 4.03 | 11 | 2.73 | 2.96e-03 |
| uvc_low_all_up | Up-regulated at any timepoint following treatment of WS1 human skin fibroblasts with UVC at a low dose (10 J/m^2) (clusters a1-a4) | 33 | 0.08 | 2 | 24.52 | 3.07e-03 |
| alk1_hmvec_2hr_up | Up-regulated 2 hr following constitutive activation of TGFbeta receptor ALK1, which activates the Smad1/5 pathway, in human microvessel endothelial cells (HMVEC). | 593 | 1.47 | 6 | 4.09 | 3.94e-03 |
| alk1_hmvec_4hr_up | Up-regulated 4 hr following constitutive activation of TGFbeta receptor ALK1, which activates the Smad1/5 pathway, in human microvessel endothelial cells (HMVEC). | 593 | 1.47 | 6 | 4.09 | 3.94e-03 |
| il2_pbmc_24hr_dn | Down-regulated at 24 hr following treatment of peripheral blood mononuclear cells (PBMC) with recombinant IL-2. | 646 | 1.60 | 6 | 3.76 | 5.91e-03 |
| tgfb_hmvec_4hr_dn | Down-regulated 4 hr following treatment of human microvessel endothelial cells (HMVEC) with TGFbeta. | 1321 | 3.27 | 9 | 2.76 | 6.41e-03 |
| bcnu_glioma_nomgmt_48hrs_dn | Down-regulated in an MGMT-deficient glioma cell line (A172) at 48 hours following treatment with BCNU | 50 | 0.12 | 2 | 16.18 | 6.92e-03 |
| bay_pbmc_6hr_up | Up-regulated at 6 hr following treatment of peripheral blood mononuclear cells (PBMC) with BAY 50-4798, an IL-2 receptor agonist. | 475 | 1.17 | 5 | 4.26 | 7.01e-03 |
| serum_fibroblast_core_dn | Core group of genes consistently down-regulated following exposure to serum in a variety of human fibroblast cell lines (higher expression in quiescent cells, not cell-cycle dependent) | 319 | 0.79 | 4 | 5.07 | 8.55e-03 |